Lilie Lin, MD
Radiation Oncology · Houston, TXNPI 1831283340
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,135 of the $3,408 with a category attached, or 62.7%. Merck accounts for 62.7% of it on its own, with 4 other manufacturers making up the rest. 2024 is the largest year on record at $2,135, 2.2 times the $956 reported in 2019.
Across 12 payments — averaging $283.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- AstraZeneca$905
- Elekta, Inc.$133
- Telix Pharmaceuticals$128
- Angiodynamics, Inc.$106
Across 12 payments — averaging $101,122 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$603K
- AstraZeneca$490K
- Siemens Medical Solutions USA, Inc.$120K
What the payments were for
- Consulting fees$2,13563%
- Travel & lodging$65419%
- Food & beverage$61818%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $2,135 |
| AstraZeneca | 8 | $905 |
| Elekta, Inc. | 1 | $133 |
| Telix Pharmaceuticals | 1 | $128 |
| Angiodynamics, Inc. | 1 | $106 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$712
- ILLUCCIX$257
- ELEKTA MEDICAL LINEAR ACCELERATOR$133
How this compares
$3,408 in reported general payments places this provider in the 80th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Houston
- James WelshHouston$421K
- Stephen ChunHouston$344K
- Chad TangHouston$183K
- Phuoc TranHouston$177K
- Steven LinHouston$105K
- Benjamin SchrankHouston$100K
- Abhilasha PatelHouston$76K
- Joe ChangHouston$50K
- Daniel GomezHouston$47K
- David RosenthalHouston$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.